Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

657
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
657
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

27
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
27
Urinary Tract Infection IV: Nursing Management01:17

Urinary Tract Infection IV: Nursing Management

517
In managing urinary tract infections (UTIs) in nursing, a comprehensive assessment is essential. Begin by gathering subjective data, such as the patient’s complaints of dysuria (painful urination), urinary frequency, urgency, suprapubic pain, and any lower abdominal discomfort. This information can be complemented by questions regarding previous UTIs, sexual activity, and personal hygiene practices, which can provide insight into risk factors. Objective assessment should focus on signs...
517
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

29
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
29
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

3.6K
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
3.6K
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

16
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
16

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nurse-Specific Assessment and Management of Neurotoxicity Associated With Immunotherapy: An Integrative Literature Review.

Journal of pediatric hematology/oncology nursing·2026
Same author

Using Natural Language Processing to Identify Symptomatic Adverse Events in Pediatric Oncology: Tutorial for Clinician Researchers.

JMIR bioinformatics and biotechnology·2025
Same author

AML Care at Home: An Evidence-Based Toolkit to Personalize the Care Setting for Recovery From Pediatric AML Chemotherapy.

JCO oncology practice·2025
Same author

Electronic Communication Between Children's Caregivers and Health Care Teams: Scoping Review on Parental Caregiver's Perceptions and Experience.

JMIR pediatrics and parenting·2024
Same author

Dose-limiting mucositis: friend or foe?

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2023
Same author

Why Psychosocial Care Matters: Parent Preparedness and Understanding Predict Psychosocial Function When Children Return to School After Cancer.

Journal of pediatric hematology/oncology nursing·2023

Related Experiment Video

Updated: Feb 20, 2026

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

18.6K

Dinutuximab-Associated Neurotoxicity: Incidence, Presentation, Risk Factors, and Nursing Interventions.

Kristen L Dalton1,2, Erin A Armideo1, Shannon L Markert1

  • 1Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.

Journal of Pediatric Hematology/Oncology Nursing
|February 18, 2026
PubMed
Summary

Dinutuximab-associated neurotoxicity is common in neuroblastoma treatment, affecting most patients early. Urinary retention and visual changes are key symptoms, with universal risk factors suggesting a need for targeted monitoring and interventions.

Keywords:
adverse effectsdinutuximabimmunotherapyneurotoxicitynursing care

More Related Videos

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.9K

Related Experiment Videos

Last Updated: Feb 20, 2026

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

18.6K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.9K

Area of Science:

  • Oncology
  • Neuroscience
  • Pharmacology

Background:

  • Dinutuximab, a GD2-directed monoclonal antibody, is integral to neuroblastoma therapy.
  • Significant knowledge gaps exist regarding dinutuximab-induced neurotoxicity's incidence, risk factors, and management.

Purpose of the Study:

  • To characterize neurotoxicity symptoms associated with dinutuximab.
  • To summarize nursing interventions for managing neurotoxicity.
  • To identify potential risk factors for dinutuximab-related neurotoxicity.

Main Methods:

  • Retrospective descriptive study of 437 dinutuximab cycles in 65 patients (2018-2023).
  • Analysis of patient demographics, clinical variables, neurotoxicity occurrences, and nursing responses.
  • Evaluation of associations between variables and neurotoxicity incidence.

Main Results:

  • Neurotoxicity occurred in 36.4% of cycles, affecting 83.1% of patients, with symptoms appearing early (Day 1 in 73.7%).
  • Common symptoms included urinary retention (66.2%) and visual changes (16.9%).
  • Neurotoxicity was not significantly related to age, sex, upfront vs. relapsed therapy, or Curie score.

Conclusions:

  • Dinutuximab-associated neurotoxicity is frequent, often manifests early, and affects a high percentage of patients.
  • Risk appears universal, irrespective of demographics or clinical factors.
  • Development and testing of targeted neurologic monitoring and nursing interventions are crucial for safe dinutuximab administration.